BACKGROUND: Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC). This study, part of the ENTHUSE (EndoTHelin A USE) phase III programme, evaluated the efficacy and safety of the oral specific endothelin (ET) A receptor antagonist zibotentan vs placebo in patients with non-metastatic CRPC (non-mCRPC). METHODS: This was a multicentre, randomized, double-blind, phase III study. Patients (n ¼ 1421) with non-mCRPC and biochemical progression (determined by rising serum PSA levels) were randomized to receive zibotentan 10 mg or placebo once daily. Based on the lack of efficacy signal in another ENTHUSE phase III study, an interim analysis was performed to determine whether the study was likely to achieve the co-primary objectives of improved overall survival (OS) and progression-free survival (PFS). RESULTS: Criteria for continuation of this study were not met. A total of 79 deaths and 293 progression events were recorded at final data cutoff. Zibotentan-treated patients did not significantly differ from placebo-treated patients for OS (hazard ratio (HR): 1.13; 95% confidence interval (CI): 0.73-1.76, P ¼ 0.589) or PFS (HR: 0.89; 95% CI: 0.71-1.12, P ¼ 0.330). The most commonly reported adverse events in zibotentan-treated patients were peripheral oedema (37.7%), headache (26.2%) and nasal congestion (24.9%); each occurred with 415% higher incidence than in the placebo group. CONCLUSIONS: This trial was terminated early because of failure at interim analysis of the efficacy data to meet the defined criteria for continuation. Owing to the absence of demonstrable survival benefits in the ENTHUSE clinical studies, zibotentan is no longer under investigation as a potential treatment for prostate cancer.
INTRODUCTION
Prostate cancer is the second most frequently diagnosed cancer in men worldwide. 1 Patients with advanced disease invariably develop castration-resistant prostate cancer (CRPC). 2 A substantial proportion of these patients can remain asymptomatic for several years, 3, 4 and current treatment depends on a number of factors; pivotally, the presence or absence of metastases. In fact, there is no standard of care approach for these patients, and there is no therapy that has been shown to impact survival in men with non-metastatic CRPC (non-mCRPC).
Endothelin (ET)-mediated signalling has been implicated in the progression of prostate cancer and the development of bone metastases. 5, 6 Specifically, binding of ET-1 to the ET A receptor facilitates various processes that promote prostate cancer growth, including tumour angiogenesis and invasion, inhibition of apoptosis and metastasis. 5, 6 Zibotentan (ZD4054), an oral, specific ET A receptor antagonist, has demonstrated survival benefit in a phase II study of patients with mCRPC. 7, 8 These promising findings led to the initiation of a large international phase III trial programme (ENTHUSE; ENdoTHelin A USE) investigating zibotentan treatment in patients with mCRPC and non-mCRPC.
We report the findings from the phase III ENTHUSE study assessing the efficacy and safety of zibotentan vs placebo in nonmCRPC (ENTHUSE M0; clinicaltrials.gov NCT00626548). The trial was terminated early because of failure to meet defined efficacy criteria for continuation at interim analysis.
MATERIALS AND METHODS Patients
Adult males with histologically or cytologically confirmed adenocarcinoma of the prostate who were surgically or continuously medically castrated (stable treatment for X8 weeks before study initiation) with serum testosterone levels p2.4 nmol l À 1 or 70 ng dl À 1 (lower limit of quantification in many centres participating in this trial) and no evidence of metastatic disease, local recurrence or pelvic lymph node disease based on scans of the chest, abdomen/pelvis or bone were eligible for study inclusion. Patients were also required to have biochemical progression of prostate cancer, documented while castrate and defined as X2 stepwise increases in PSA over a period of X1 month, with X14 days between each measurement. The final PSA value had to be X1.2 ng ml À 1 (patients with radical prostatectomy) or 5.0 ng ml À 1 (all other patients), representing an increase in X50% or absolute increase in X10 ng ml À 1 over the first of the three PSA values selected for assessment. Further details on patient eligibility criteria have been reported previously. 9 All patients provided written informed consent before participation in the study. Approval of the study protocol and consent forms was obtained from the relevant ethical review board or committee at each investigational site.
Study design
This was a multicentre, randomized, double-blind, phase III study. Patients were stratified by centre and randomized 1:1 to receive oral zibotentan 10 mg or placebo once daily (Figure 1a) . At the investigator's discretion, patients were permitted additional standard prostate cancer therapies in conjunction with study treatment, including regular follow-up; symptomatic therapy for pain control or urinary obstruction; chemotherapy; and secondary hormonal manipulations such as oestrogen-based preparations, anti-androgens, ketoconazole, megestrol or prednisolone. Patients were allowed to continue oral bisphosphonate therapy if the dose was stabilized X4 weeks before the start of study treatment, and maintained for the duration of the study.
The absence of a significant survival benefit in the phase III ENTHUSE M1 study (NCT00554229), 10 prompted an interim analysis of data in this study to assess the feasibility of achieving the co-primary objectives of the study, the findings of which precipitated early termination of the study (data cutoff (DCO): 1 October 2010). As a consequence, all patients were discontinued from study treatment, with collection of data limited thereafter to safety end points until final DCO (27 June 2011).
Study end points and evaluations
Co-primary end points. Overall survival (OS), defined as time from randomization to death from any cause, and progression-free survival (PFS) were the co-primary end points of this study. PFS was defined as the time from randomization to documentation of progressive metastatic disease, with progression classified as any of the following: X1 new bone lesions on bone scan (confirmed by computed tomography, magnetic resonance imaging or X-ray); development of malignant visceral disease on computed tomography/magnetic resonance imaging; or death in the absence of progression. All patients underwent a bone scan and computed tomography or magnetic resonance imaging scan of the abdomen and pelvis (and additional regions, where clinically indicated) at study entry and then every 32 weeks until progression.
Secondary end points. Secondary objectives included time to PSA or symptomatic progression, health-related quality of life (functional assessment of cancer therapy for prostate cancer) and safety. Owing to the early termination of this study, the secondary efficacy objectives were not subjected to analysis.
Safety and tolerability were monitored throughout the study, and assessment encompassed the incidence and severity of adverse events (AEs; graded according to the National Cancer Institute for Common Terminology Criteria for Adverse Events (CTCAE) version 3.0), laboratory data (clinical chemistry, haematology, and urinalysis parameters), electrocardiograms, vital signs and other physical examination findings. AEs were monitored at study entry and then every 28 days throughout the study. If a patient discontinued study treatment before a progression criterion was met, AEs were monitored for the first 28 days off study treatment. The patient was subsequently followed-up every 16 weeks until progression. For patients who stopped study treatment after progression, AEs continued to be collected for the first 28 days off study treatment. For patients who continued study treatment after progression, AEs continued to be monitored every 6 months. Patients were actively questioned by means of a possible congestive heart failure (CHF) questionnaire at every visit, to identify possible signs and symptoms of cardiac failure.
Statistical analysis
No interim analysis was planned before the trial was activated. Before the decision to perform the interim analysis, the statistical plan required recruitment of 1500 patients. Originally, the study was sized to have (i) 90% power to demonstrate a statistically significant effect in OS indicated by a hazard ratio (HR) for zibotentan vs placebo of 0.75, assuming a median OS for the placebo group of approximately 47 months at the 4% significance level; (ii) 485% power to demonstrate a statistically significant difference in PFS indicated by a HR of 0.75, assuming a median PFS for the placebo group of 24 months, at the 1% significance level. Based on a recruitment period of 18 months and an OS of 47 months, it was estimated that 590 deaths would occur approximately 52 months after the first patient entered the study.
The HR for the co-primary objectives of OS and PFS formed the basis for the continue-stop decision matrix that was developed for the interim analysis. Thus, continuation of the study would occur if HR p0.75 for OS, or 0.75oHRp1.1 for OS plus HR o0.8 for PFS. Conversely, discontinuation of the study would occur if HR 41.1 for OS, or 0.75oHRp1.1 for OS plus HR X0.8 for PFS. However, if positive trends were observed in both OS (0.75pHRp0.85) and PFS (0.8pHRp0.85), the study could continue.
Analyses of efficacy end points (OS and PFS) were performed on an intent-to-treat basis using a log-rank test, and are presented by means of Kaplan-Meier survival curves. The numbers of events at the time of the interim analysis are presented with corresponding HR estimates, 95% confidence intervals (CIs) and P-values. Safety data from all randomized patients who received at least one dose of study treatment (safety population) are presented descriptively.
RESULTS

Study population
Overall, 2577 patients were enrolled in the study between January 2008 and May 2011 (Figure 1b) . A total of 1155 (45%) patients failed screening, most commonly because of detection of metastatic disease (32% of all enroled patients; 71% of screening failures). 9 Consequently, 1421 patients were randomized and 1415 patients received treatment with zibotentan (n ¼ 703) or placebo (n ¼ 712).
The majority of patients were Caucasian (70.4%), with a median age of 73 years (range 44-93). Demographics and baseline characteristics (Table 1 ) and anticancer treatments received post randomization (Table 2) were similar between the two treatment arms.
All patients were discontinued from treatment following the outcome of the interim analysis. Patients discontinued study treatment because of AEs (n ¼ 208; 14.6%), withdrawal of consent (n ¼ 88; 6.2%), non-compliance (n ¼ 15; 1.1%) and loss to followup (n ¼ 4; 0.3%); the remaining 1100 (77.4%) patients discontinued treatment following the outcome of the interim analysis and subsequent study termination.
Efficacy
All patients who were randomized up to and including 1 September 2010 were included in the interim analysis of efficacy (zibotentan: n ¼ 592; placebo: n ¼ 589). Originally, the primary analysis was to be carried out when 410 deaths and 690 progression events had occurred. At the interim analysis, 79 deaths and 293 progression events had occurred.
Co-primary objectives: OS and PFS. In total, 79 deaths (zibotentan: n ¼ 40 (6.8%); placebo: n ¼ 39 (6.6%)) and 293 progression events (zibotentan: n ¼ 131 (22.1%); placebo: n ¼ 162 (27.5%)) were recorded at DCO (27 June 2011).
The HR for OS did not meet the decision criteria for continuation of the study (HR: 1.13; 95% CI: 0.73-1.76, P ¼ 0.59; Figure 2a ). The HR for the co-primary end point of PFS was X0.8 (HR: 0.89; 95% CI: 0.71-1.12, P ¼ 0.33; Figure 2b ) and, in combination with the HR for OS, did not meet the decision criteria for continuation of the study.
Using predictive power calculations, we determined the probabilities of the trial ultimately achieving a positive outcome based on the results obtained at the early analysis. For OS, given the early analysis results, there was a 7% chance of the trial ultimately achieving a significant result had the trial completed according to the original size. For PFS, based on the early analysis results, there was a 4% chance of ultimately achieving a HR o0.75, which would have been assessed as a successful outcome. a Scans were only performed every 32 weeks. After the first analysis, which occurred when approximately 410 deaths had occurred (and it had been anticipated that there would be 690 progression events), the assessments undertaken every 32 weeks for progression were no longer required. Patients were followed for progression, only as clinically indicated, and survival. Patients continuing on study treatment after the final analysis (approximately 590 deaths) had occurred were to be followed for serious adverse events (SAE) data only.
c Patients who were discontinued from study treatment for safety and tolerability reasons. (b) CONSORT diagram.
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Safety
Safety results are derived from the final DCO (27 June 2011), at which time all patients had discontinued study treatment and were no longer enroled on this study. The median total duration of exposure to zibotentan was 7.95 (range: 0-35.8) months and 10.69 (0.2-34.3) months for placebo. At least one AE was experienced by 611 (86.9%) patients in the zibotentan and 560 (78.7%) patients in the placebo group. The most commonly reported AEs (all grades) in zibotentan-treated patients were peripheral oedema (37.7%), headache (26.2%) and nasal congestion (24.9%), each of which occurred with 415% higher incidence than was observed in the placebo group (Table 3) . A similar incidence of CTCAE grade X3 events were reported among zibotentan-treated (172; 24.5%) and placebotreated (156; 21.9%) patients. In the zibotentan group, the most frequent grade X3 AEs were headache (1.6% vs 0% for placebo), anaemia (1.3% vs 0.7%), neutropenia (1.3% vs 1.3%) and peripheral oedema (1.3% vs 0.3%). Serious AEs were reported in 139 (19.8%) and 133 (18.7%) of patients in the zibotentan and placebo groups, respectively. AEs led to treatment discontinuation in more patients receiving zibotentan (162; 23.0%) than those receiving placebo (44; 6.2%); primarily due to higher incidences of peripheral oedema (4.6% vs 0.6%), nasal congestion (3.6% vs 0%) and headache (3.1% vs 0.1%). Overall, 14 (2.0%) patients experienced fatal AEs in each treatment group.
Cardiac failure events, actively solicited following a signal in a previous phase II study, 8 and other related terms suggestive of CHF AEs (cardiac failure congestive, left ventricular dysfunction, cardiac failure acute or chronic) occurred in 28 (4.0%) zibotentantreated patients compared with 10 (1.4%) receiving placebo. Time to onset for CHF AEs was within 60 days of initiation of treatment for 19 of the 28 patients in the zibotentan group. Heart failure tended to occur within the first 3 months of dosing with zibotentan (range, 1-502 days). CHF events resolved in the majority (21 of 26) of zibotentan-treated patients who received treatment. CHF AEs resulted in death in the placebo group alone (n ¼ 2; cardiac failure and chronic cardiac failure). In total, 12 of 28 patients who had CHF AEs in the zibotentan group had events that were considered to be serious AEs. Of the 28 patients who reported CHF AEs in the zibotentan group, 26 patients received treatment for this event, and the majority of events (21 patients) resolved, either without interrupting zibotentan treatment (8 patients), or after temporary (2 patients) or permanent (11 patients) discontinuation of zibotentan treatment. With the exception of reductions in haemoglobin, platelet count and white cell count in zibotentan-treated patients, no clinically relevant changes in laboratory safety parameters were observed between treatment groups.
DISCUSSION
Analysis of data from this phase III study of zibotentan 10 mg vs placebo in non-mCRPC was precipitated by the findings from a partner trial (ENTHUSE M1), in which no significant improvement in survival was observed for zibotentan treatment compared with placebo in patients with CRPC that had metastasized to bone. 10 Results from this interim analysis revealed that the criteria for continuation of this study were not met; consequently, the study was terminated early. It should be noted that the early cessation of the trial (leading to reduced post-randomization power) and low numbers of observed mortality and PFS events (as evidenced by the large confidence intervals associated with end point estimates) represent a major study limitation and preclude definitive conclusions regarding the efficacy of the study treatment.
The ENTHUSE programme of phase III clinical trials was designed to evaluate the efficacy and safety of zibotentan as monotherapy in mCRPC (ENTHUSE M1) and non-mCRPC (ENTHUSE M0), and as combination therapy with docetaxel in patients with mCRPC (ENTHUSE M1C). Results from the two monotherapy studies documented a failure of zibotentan to demonstrate a significant benefit over placebo, irrespective of metastasis. 10 Encouraging preclinical data and initial clinical evidence supported investigation of zibotentan in combination with docetaxel in the phase III setting; [11] [12] [13] [14] however, ENTHUSE M1C failed to confirm superiority for the zibotentan and docetaxel combination in mCRPC. 15 Collectively, results from the ENTHUSE programme, while disappointing, are consistent with those of the selective ET A receptor antagonist atrasentan, which produced positive phase II data, 11, 16, 17 but which also failed to significantly impact disease progression in the phase III setting. [18] [19] [20] Zibotentan was generally well tolerated in this patient population, with observed safety and tolerability data consistent with the known profile of zibotentan. Pharmacological consequences of ET A antagonism by zibotentan are largely the result of vasodilation. 21 Thus, events of headache, nasal congestion/rhinitis, peripheral oedema and reductions in blood pressure and haemoglobin with zibotentan in this study were not unexpected and reflect reports across an extensive clinical programme. 7, 8, 10, 21, 22 CHF is a common and significant cause of death in patients with prostate cancer; 23, 24 there was no evidence to suggest an increased risk in zibotentan-treated patients in this study. Indeed, the incidence of cardiac failure events in the zibotentan (4%) and placebo groups (1%) are comparable to reported incidences from other phase III studies in the ENTHUSE clinical programme (zibotentan: 6%; placebo: 2%) and a phase III trial of atrasentan (atrasentan 10 mg: 5%; placebo: 1%). 18 The Figure 2 . Kaplan-Meier curves of overall survival (a) and progression-free survival (b). A high screening failure rate was observed in this study, the potential reasons for which have been examined and reported separately. 9 The most common reason (comprising 71% of all screening failures) was detection of metastatic disease. Although the frequency of the most common reasons for screening failure were similar across investigator specialties (urology vs oncology) and within geographical regions, greater variation in the overall failure rate was observed between geographical areas (from 38% in the Asia Pacific region to 65% in the Middle East). The prevalence of asymptomatic metastases in men thought to have non-mCRPC should be factored into the recruitment design of future clinical trials, which should utilize more sensitive markers of progression that ideally obviate the requirement for assessment by imaging techniques.
To date, there are no approved agents for patients with nonmCRPC despite numerous other attempts to study this disease state with zoledronic acid, 25 atrasentan [18] [19] [20] and, most recently, denosumab;
26 of all these phase III studies, only the latter trial (denosumab) achieved complete accrual. Although none of these studies were positive in terms of OS, denosumab did delay time to bone metastases, yet did not receive Food and Drug Administration approval for use in this setting. 27 Hence, this disease state is very challenging to study because of its intrinsic heterogeneity, longer natural history and, in recent years, the availability of numerous downstream therapies that modify outcome and could confound the results of a trial in non-mCRPC. 28 In conclusion, this study was terminated early on the basis of results from an interim analysis indicating that zibotentan 10 mg day À 1 was unlikely to meet its co-primary end points of OS and PFS. As a result of the lack of efficacy in the ENTHUSE trials, zibotentan is no longer being investigated as a potential treatment for patients with prostate cancer.
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